

Table 2e. Antibody Performance, Weeks 3 to 5 – IgM or IgG

IgM or IgG	Week 3			Week 4			Week 5		
Sensitivity	0.94 (95% CI: 0.92 to 0.96)			0.88 (95% CI: 0.78 to 0.94)			NR		
Specificity	0.97 (95% CI: 0.95 to 0.98)								
Outcome	Effect per 1,000 patients tested								
	Pre-test Probability								
	1% ^a	10% ^b	40% ^c	1% ^a	10% ^b	40% ^c	1% ^a	10% ^b	40% ^c
True positives (patients with COVID-19)	9 (9 to 10)	94 (92 to 96)	376 (368 to 384)	9 (8 to 9)	88 (78 to 94)	352 (312 to 376)	NR	NR	NR
False negatives (patients incorrectly classified as not having COVID-19)	1 (0 to 1)	4 (6 to 8)	24 (16 to 32)	1 (1 to 2)	12 (6 to 22)	48 (24 to 88)	NR	NR	NR
Quality of the evidence	6 studies, 1038 patients ⊕⊕○○ LOW ^{d, e}			2 studies, 216 patients ⊕○○○ VERY LOW ^{d, e, f}			NR		
	pre-test probability of 1% ^a			pre-test probability of 10% ^b			pre-test probability of 40% ^c		
True negatives (patients without COVID-19)	960 (941 to 970)			873 (855 to 882)			582 (570 to 588)		
False positives (patients incorrectly classified as having COVID-19)	30 (20 to 50)			27 (18 to 45)			18 (12 to 30)		
Quality of Evidence	11 studies, 5660 patients ⊕⊕○○ LOW ^{d, e}								
<p>a. Typically seen in general population in areas that are not hotspots</p> <p>b. Typically seen in general population in high risk populations</p> <p>c. Typically seen in general population in exposed and nursing homes</p> <p>d. The case-control design leads to a serious risk of bias</p> <p>e. Unexplained inconsistency observed with considerably variable sensitivity. Sensitivity Ranges: C3: 0.80-1.00, C4: 0.75-0.94</p> <p>f. Considering the Upper vs Lower limits of the sensitivity's confidence interval would lead to different clinical decisions.</p>									